All In Biotech

Drug Trial Radar · NCT01037205

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Last checked: Nov 19, 2026Latest source record: Apr 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Dec 2009

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH)
First posted
Dec 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will seek to enroll adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive diagnostic test for influenza virus (IFV).

Conditions

  • Influenza

Interventions

  • DAS181 dry powder, formulation F02Drug

    10 mg delivered dose DAS181 in clear HPMC #3 Capsules

  • Respitose ML006 (DMV-Fonterra)Drug

    Lactose monohydrate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Level of influenza viral load as Area Under the Curve at Day 5 (AUC0 d5) as measured by a) quantitative polymerase chain reaction (quantitative PCR) and b) 50% tissue culture infectious dose (TCID50) in cell cultureTime frame: 28 days
  2. Safety and toxicity profile: Unacceptable Serious Adverse EventsTime frame: 28 days

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Carmichael, California

  • Site not named

    Chula Vista, California

  • Site not named

    La Mesa, California

  • Site not named

    Lincoln, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Hialeah, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Covington, Louisiana

  • Site not named

    Silver Spring, Maryland

  • Site not named

    North Dartmouth, Massachusetts

  • Site not named

    Bellevue, Nebraska

  • Site not named

    Henderson, Nevada

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Stony Brook, New York

  • Site not named

    Canton, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Franklin, Ohio

  • Site not named

    Groveport, Ohio

  • Site not named

    Miamisburg, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Ashland, Oregon

  • Site not named

    Lansdale, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Myrtle Beach, South Carolina

  • Site not named

    Simpsonville, South Carolina

  • Site not named

    Rapid City, South Dakota

  • Site not named

    Johnson City, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Georgetown, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    West Point, Utah

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.